fashion -WSS

fashion

author：hotspot 2025-09-29 01:06:08 - browse：4528

The New York Stock Exchange (NYSE) — Spencer Platt/Getty Images

Biohaven Pharmaceuticals said Wednesday that a new type of experimental medicine reduced levels of a disease-causing immune molecule by up to 37% in an early-stage study of human volunteers — a result that the company called “positive” as a proof of concept but that also fell short of investor expectations.

The drug, called BHV-1300, belongs to a new class of antibody medicines that shuttle harmful proteins to the liver so they can be removed from the body. BHV-1300 is specifically designed to reduce levels of an autoantibody called IgG that is implicated in rheumatoid arthritis, myasthenia gravis, and other autoimmune disorders.

In its Phase 1 study, Biohaven tested four escalating doses of BHV-1300 in healthy volunteers, showing a reduction in levels of IgG of 5%, 15%, 30%, and 37%, respectively, the company said. The reductions in IgG levels, which occurred relatively quickly in just four to five days, did not cause significant, adverse changes in liver enzyme levels, Biohaven added — an important safety check given the mechanism of the drug.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The high cost of giving birth even with insurance
Next article： Researchers explore possible ties between long Covid, menopause

hotspot

WSS

Sweeping indictment could be Trump's biggest legal challenge yet: ANALYSIS

FDA gives detailed accounting of AI

Why health workers in Gaza are injured or die at high rates

CEOs share strategies for surviving biotech slump

STAT Summit: Biotech founders on deal

First Opinion Podcast: Long Covid needs a new approach

focus

fashion

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

entertainment

Hollywood unions extend contract negotiations for actors

What to know about the judge who will handle the Trump case

Anesthesiologist group: stop taking Ozempic before surgery

Biogen’s boardroom scandal saddles CEO with first crisis

United colonoscopy coverage change 'may cost lives,' doctors say

Idaho college killings prosecutors challenge defense's grand jury claims

Peter Hotez and the public health issue of online harassment

Mark Cuban is blaming the wrong people for high drug costs

Alkermes shareholders re

Eli Lilly expects to double planned employment in Boston center

leisure time

Illumina slashes 2023 revenue projections yet again

Medicare reduced heart disease by changing how it pays doctors

Surge in Apellis stock fueled by confidence in safety of its eye drug

The EU Joint Clinical Assessment needs to live up to its promise

Novo Nordisk touts Wegovy study, but still struggling with supply

Eli Lilly expects to double planned employment in Boston center

explore

focus

hotspot

leisure time